Skip to main content
. 2019 Jun 8;11(6):795. doi: 10.3390/cancers11060795

Figure 3.

Figure 3

Basal HNSCC cells are sensitive to therapeutic combinations. (A) Boxplot of the Bliss synergy scores obtained on basal and non-basal HNSCC cell lines upon treatment with the shown therapeutic combination (Cetuximab and Trastuzumab; Afatinib and Trastuzumab; Afatinib and Gedatosilib). The Bliss scores were found to be significantly higher (t-test p-values are shown) in basal cells. (B) Boxplot of the Bliss synergy scores obtained on wild-type (WT) and CDKN2A mutant (M) HNSCC cell lines upon treatment with Cetuximab and Gedatosilib. CDKN2A mutations are significantly associated with higher Bliss scores. (C) Analysis of the clonogenic survival of basal BHY and non-basal KYSE-510 cells upon treatment with Cetuximab and Gedatosilib, and with Cetuximab and Trastuzumab. BHY cells displayed a significantly higher sensitivity to therapeutic combinations. Mean survival fractions and standard errors from three independent experiments are shown.